{"url_path":"/sec/plyx/8-k/2026-07-21/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-21","source_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-080041-index.html","accession_number":"0001213900-26-080041","cik":"0002075320","ticker":"PLYX","issuer_name":"Polaryx Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2075320/0001213900-26-080041-index.html","primary_entity_key":"0002075320","primary_entity_name":"Polaryx Therapeutics, Inc."},"word_count":299,"has_tables":true,"body_markdown":"false\n0002075320\n\n0002075320\n\n2026-07-19\n2026-07-19\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n** **\n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 OR 15(d) of The Securities\nExchange Act of 1934**\n\n \n\n**Date of Report (Date of earliest event reported):\nJuly 19, 2026**\n\n \n\n**Polaryx Therapeutics, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**\n \n**001-43080**\n \n**47-3393659**\n\n(State or other jurisdiction\n \n(Commission File Number)\n \n(IRS Employer\n\nof incorporation)\n \n\n \nIdentification No.)\n\n \n\n**South Tower, 140 E Ridgewood Avenue, Suite 415**\n\n**Paramus****,\nNJ 07652**\n\n(Address of principal executive offices) (Zip Code)\n\n \n\n**(201) 940-7236**\n\nRegistrant’s telephone number, including\narea code\n\n \n\nCheck the appropriate box below if the Form 8-K\nfiling is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b)\nof the Act:\n\n \n\n**Title of each class**\n \n**Trading Symbol(s)**\n \n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.0001 per share\n \nPLYX\n \nThe Nasdaq Capital Market\n\n \n\nIndicate by check mark whether the registrant\nis an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the\nSecurities Exchange Act of 1934 (§240.12b-2 of this chapter).\n\n \n\nEmerging growth company ☒\n\n \n\nIf an emerging growth company, indicate by check\nmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting\nstandards provided pursuant to Section 13(a) of the Exchange Act. ☐"}